HOME >> MEDICINE >> NEWS
Pharmaceutical industry still failing health needs of less-developed countries

The third article about the role of the pharmaceutical industry in medicine--The Pharmaceutical Industry as a Medicines Provider--is published in this week's issue of THE LANCET.

David Henry from the University of Newcastle, Australia, and Joel Lexchin from the University of Toronto, Canada, discuss how rising prices of medicines are putting them beyond the reach of many people, even in rich countries. In less-developed countries, they state, millions of individuals do not have access to essential drugs, and drug development is failing to address the major health needs of these countries. The authors also comment how the prices of patented medicines usually far exceed the marginal costs of their production -- while the industry maintains that high prices and patent protection are necessary to compensate for high development costs of innovative products, there are doubts about the figures that form the basis of these claims.

David Henry comments: "The international pharmaceutical industry manufactures and distributes many good drugs, displays generosity in its philanthropic activities, and has an important role in maintenance of manufacturing standards. However, evidence shows that companies have shifted their core activities from discovery and development of innovative drugs to marketing of products that keep profit to a maximum in high-income countries."

He adds: "Access to important drugs by low-income countries is generally agreed to remain grossly inadequate. Some international manufacturers have responded to this crisis by sharp reductions in prices of some products and by donations. These moves largely seem to have been in response to external pressures, especially bad publicity and generic competition, rather than initiatives of the companies themselves. Restoration of true market forces and fair pricing of drugs is a better long term solution to shortages than 'ad hoc' donations. These issues are particularly relevant and timely
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
14-Nov-2002


Page: 1 2

Related medicine news :

1. Pharmaceutical marketing tactics hold little sway with prescribing physicians
2. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
3. Pharmaceutical Achievers
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
7. American Association of Pharmaceutical Scientists Dietary Supplements Forum examines science behind nutraceuticals
8. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
9. Pharmaceuticals and personal care products
10. New publisher announced for Journal Of Pharmaceutical Sciences
11. American Association of Pharmaceutical Scientists tapped to manage PQRI

Post Your Comments:
(Date:7/28/2014)... Cape Regional Medical Center, is ... technology solution in an effort to streamline its ... with their New Jersey health information exchange (NJSHINE). ... in New Jersey, serves the local population and ... of inpatient and outpatient services. With a strong ...
(Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
(Date:7/28/2014)... The Oakwood Foundation celebrated a major gift this ... PC that will benefit each community we serve for ... The HBWS group is among the Foundation’s largest physician ... donations. Through their latest gift, they will be one ... Classic for the next 6 years; provide state-of-the-art technology ...
(Date:7/28/2014)... one of two dopamine-producing regions in the brain was ... isoflurane or propofol. In the August issue of ... report that rats anesthetized with continuous doses of either ... up in response to electrical stimulation delivered to the ... major dopamine-releasing area, the substantia nigra, did not induce ...
(Date:7/28/2014)... 2014 The report, “Blowing Agents ... - Trends and Forecasts to 2019” defines and ... and forecasting of the global consumption volume and ... tables with 39 figures spread through 226 Pages ... http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are highly utilized ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
(Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
Cached News: